710943-26-3

Basic information

• Product Name: 6-AMINOMETHYL INDAZOLE
• Synonyms: 6-AMINOMETHYL INDAZOLE;6-aminomethyl-1H-indazole;(1H-indazol-6-yl)methanamine;1-(1H-indazol-6-yl)methanamine;(1H-Indazol-6-yl)methylamine;C-(1H-Indazol-6-yl)-methylamine
• CAS NO: 710943-26-3
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.18
• Product Categories: Building Blocks;Indazole
• Mol File: 710943-26-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 352.1 °C at 760 mmHg
• Flash Point: 193.8 °C
• Appearance: /
• Density: 1.278 g/cm³
• Vapor Pressure: 3.93E-05mmHg at 25°C
• Refractive Index: 1.712
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.27±0.40(Predicted)
• CAS DataBase Reference: 6-AMINOMETHYL INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINOMETHYL INDAZOLE(710943-26-3)
• EPA Substance Registry System: 6-AMINOMETHYL INDAZOLE(710943-26-3)

Safety Data

• RIDADR: UN3439
• Hazardous Substances Data: 710943-26-3(Hazardous Substances Data)

Usage

General Description

6-Aminomethyl Indazole is a chemical compound primarily used in scientific research as an intermediate chemical in the manufacture of various pharmaceuticals. It is characterized by its molecular formula C8H9N3 and its systematic name 1H-Indazole-6-methanamine. 6-AMINOMETHYL INDAZOLE features an indazole group, which is a common structure in many bioactive molecules. Therefore, it is an important component in the synthesis of novel biologically active compounds for drug development. However, detailed toxicological properties and potential health effects associated with exposure to 6-Aminomethyl Indazole have not been extensively explored.

InChI:InChI=1/C8H9N3/c9-4-6-1-2-7-5-10-11-8(7)3-6/h1-3,5H,4,9H2,(H,10,11)

Upstream product

• 141290-59-7 1H-indazole-6-carbonitrile 

Downstream Products

• 1612182-03-2 6-(2,3-dimethylphenyl)-4-N-(1H-indazol-6-ylmethyl)pyrimidine-2,4-diamine 

Relevant articles and documents

Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases

Nitric oxide (NO) is an essential endogenous mediator with a physiological role in the central nervous system as neurotransmitter and neuromodulator. A growing number of studies have demonstrated that abnormal nitrergic signaling is a crucial event in the development of neurodegeneration. In particular, the uncontrolled production of NO by neuronal nitric oxide synthase (nNOS) is observed in several neurodegenerative diseases. Moreover, it is well recognized that specific isoforms of human carbonic anhydrase (hCA) physiologically modulate crucial pathways of signal processing and that low expression of CA affects cognition, leading to mental retardation, Alzheimer′s disease, and aging-related cognitive impairments. In light of this, dual agents that are able to target both NOS (inhibition) and CA (activation) could be useful drug candidates for the treatment of Alzheimer′s disease, aging, and other neurodegenerative diseases. In the present work, we show the design, synthesis, and in vitro biological evaluation of new nitrogen-based heterocyclic compounds. Among the tested molecules, 2-amino-3-(4-hydroxyphenyl)-N-(1H-indazol-5-yl)propanamide hydrochloride (10 b) was revealed to be a potent dual agent, able to act as a selective nNOS inhibitor and activator of the hCA I isoform.